SCHEMBL8259574

SCHEMBL8259574

CC(C)(C)OC(=O)N1CCN(c2cc(O)ccc2F)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.52
GPR119 Q8TDV5 5/20 0.48
SMARCA2 P51531 1/20 0.48
SMARCA4 P51532 1/20 0.48
PBRM1 Q86U86 1/20 0.48
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
LMNA P02545 1/20 0.48
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45
PDK2 Q15119 2/20 0.45
GRIA1 P42261 1/20 0.45
CYP3A4 P08684 1/20 0.44
CYP3A5 P20815 1/20 0.44
HTT P42858 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PDK1 Q15118 1/20 0.43
PDK3 Q15120 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4951947 0.89 ESR2 (0.52) ESR2GPR119SMARCA2SMARCA4PBRM1
SCHEMBL30221986 0.89 ESR2 (0.52) ESR2GPR119SMARCA2SMARCA4PBRM1
SCHEMBL20657938 0.86 MEN1 (0.55) GPR119SMARCA2SMARCA4PBRM1ALDH1A1
SCHEMBL17658993 0.86 ESR2 (0.54) ESR2GPR119SMARCA2SMARCA4PBRM1
SCHEMBL1613019 0.85 NR1H2 (0.53) GPR119SMARCA2SMARCA4PBRM1ALDH1A1
SCHEMBL30998086 0.85 NR1H2 (0.53) GPR119SMARCA2SMARCA4PBRM1ALDH1A1
SCHEMBL21937028 0.84 MAPT (0.51) GPR119SMARCA2SMARCA4PBRM1ALDH1A1
SCHEMBL24215767 0.84 GPR119 (0.47) GPR119SMARCA2SMARCA4PBRM1ALDH1A1
SCHEMBL8221000 0.84 L3MBTL1 (0.59) GPR119ALDH1A1MAPTLMNAMEN1
SCHEMBL12516958 0.84 SMARCA2 (0.57) ESR2GPR119SMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7368449-B2 2-alkynyl- and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION (US) 2008-05-06 US disclosed
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists SCHERING CORPORATION 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220194-A1 2-Alkynyl-and 2-alkenyl-pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists ADORA2A, ADORA3, ADORA1 ESR2 2393/4885GPR119 223/4885SMARCA2 3732/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.